DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for secondary Parkinson disease — screening already-approved drugs against its 14-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSecondary Parkinson disease maps to a 14-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for secondary parkinson disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dopa decarboxylase (DDC) — DDC is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet plpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8OR9 · 1.9 Å · ligand PYRIDOXAL-5'-PHOSPHATE (PLP). Experimental structure, not a prediction.
What the evidence adds up to
The international Linked Clinical Trials programme for Parkinson’s disease, described in a 2021 review, has grown since 2010 to include seven completed and 15 ongoing clinical trials of 16 agents, all aimed at disease modification. The review does not report results from any of those trials. A 2001 article states that no treatment for Parkinson’s disease is curative, that optimal symptomatic treatment requires individualised balancing of benefits and side effects, and that neurosurgery is an option for some patients not helped by medical therapy. A 2010 article repeats that no treatment is curative, notes that recent trial results have prompted discussion about possible disease-modifying effects of new drugs, but emphasises that applying guidelines to individual patients becomes complex as the disease progresses. A 2022 chapter on clinical medicine describes a decade-long global repurposing programme involving more than 20 repurposed drugs and neuroprotective trials of one to two years’ duration in Parkinson’s disease, but again provides no efficacy data.
None of the four abstracts present concrete numbers for survival, response rates, or sample sizes. No abstract reports a positive or negative result from any repurposed drug trial. The 2022 chapter states that the programme has had to learn by experience alone because no how-to guide existed for establishing a major repurposing trial programme. The 2001 and 2010 articles both explicitly state that no curative treatment exists. The 2021 review describes the programme’s structure and growth but does not claim that any agent has shown disease modification in patients.
What is still missing is any published evidence from the completed trials within the iLCT programme, including whether any of the 16 agents produced a measurable effect on disease progression. The programme’s reliance on learning by experience, rather than a pre-existing template, suggests that trial design and patient stratification remain unresolved challenges. Without trial results, the programme’s ability to deliver a repurposed treatment for secondary Parkinson disease cannot be assessed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Neuroscience · 2021 · 28 citations · open access
Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
AbstractThe international Linked Clinical Trials (iLCT) program for Parkinson's to date represents one of the most comprehensive drug repurposing programs focused on one disease. Since initial planning in 2010, it has rapidly grown - giving rise to seven completed, and 15 ongoing, clinical trials of 16 agents each aimed at delivering disease modification in Parkinson's disease (PD). In this review, we will provide an overview of the history, structure, process, and progress of the program. We will also present some examples of agents that have been selected and prioritized by the program and subsequently evaluated in clinical trials. Our goal with this review is to provide a template that can be considered across other therapeutic areas.
Management of Parkinson's disease. Strategies, pitfalls, and future directions.
AbstractIn coming years Parkinson's disease will become increasingly prevalent as the baby boom generation grows older. Diagnosis often is complicated and requires careful consideration of symptoms and neurologic findings. Optimal symptomatic treatment of Parkinson's disease involves an individualized approach with each patient and ongoing evaluation of benefits versus side effects. Neurosurgical intervention is an option for some patients who are not adequately helped by medical therapy. New treatments (e.g., stem cell therapy) are currently being studied and may be available in the foreseeable future.
Therapeutic Advances in Neurological Disorders · 2010 · 6 citations · open access
Pharmacotherapy in Parkinson’s disease: case studies
AbstractParkinson's disease is a common neurodegenerative disorder with the particular feature of having various available treatments with proven efficacy. However, no treatment is curative. Recent trial results provided data for the discussion about the potential disease-modifying effect of new drugs as well as of other therapeutic strategies. The changing clinical phenotype following the progression of the disease multiplies the number of treatment targets and makes the application of recommendations from guidelines or other treatment algorithms to the individual patient a complex task. In the present manuscript, we discuss the treatment management of three case studies illustrating different stages of disease with distinct phenomenology. The proposed therapeutic alternatives are discussed based on the best data available; that is, treatment guidelines, clinical trial results or observational data.
Royal Society of Chemistry eBooks · 2022 · 1 citations
The Role of Clinical Medicine
AbstractThis chapter outlines the interface between specific, therapeutic-area focussed, drug repurposing objectives to decisions, and various approaches, surrounding the subsequent configuration and conduct of clinical trials. Ideally, these clinical trials will provide definitive proof of concept, safety, tolerability and efficacy in patient studies that lead to regulatory approval. We have never come across a how-to guide that helps with establishing and running a major drug repurposing clinical trial programme, so we have had to learn by experience alone. We therefore attempt here to offer suggestions about how such objectives can be achieved and share details of ways of solving some of the various expected and unexpected topics that are often encountered and necessitate solving in order to maintain forward momentum. To provide this practical experience we turn to, and share, what we have learned during our decade-long, global drug repurposing programme, now involving >20 repurposed drugs, and which focuses on neuroprotective clinical trials of 1–2 years duration in patients with Parkinson's disease. We concentrate on ensuring the maintenance of high quality in all aspects of our repurposing initiative as this helps it grow much faster with the active help of clinicians, non-clinical academics, patients, pharmaceutical companies and governments.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
